Gedeon Richter (RICHTER) Investor Update summary

Strategic Direction, Recent Transactions, and Industry Context

• Two major acquisitions, Mithra and BCI Pharma, have enabled full control over the E4 platform, expanded R&D capabilities, and secured global rights to DrovelisⓇ/EstelleⓇ and Donesta®.

• The Mithra deal secures the development and potential launch of Donesta, a menopause treatment, and vertically integrates R&D, manufacturing, and commercialization.

• BCI Pharma acquisition brings a proprietary library of over 2,000 molecules and strengthens early-stage research in women's health with novel kinase inhibitor capabilities.

• The women's health gap represents a $1 trillion opportunity, with significant unmet needs in endometriosis and menopause.

• These moves position the business as a leading innovator in a field largely abandoned by big pharma, providing control over key assets and future cash flows.

Market Position, Growth Ambitions, and Financial Performance

• Ambition to become the leading provider of regular contraceptives in Europe by year-end, with a target of €1bn topline sales before 2030.

• Revenue growth in women's healthcare has been strong, with full sales and marketing coverage in Europe and a growing global presence.

• Market share in key segments continues to rise, supported by innovative launches like DrovelisⓇ, EvraⓇ, and Donesta®.

• Fertility and menopause markets are high-growth areas, with new launches and expanded indications driving future sales.

• The Drovelis/Donesta franchise is expected to be earnings accretive from 2025 onwards.

Product Portfolio and Innovation

• Leading provider of oral contraceptives in Europe, with innovative products such as DrovelisⓇ and EvraⓇ enhancing market position.

• Fertility portfolio includes Bemfola, Cyclogest®, and ExEm Foam, addressing the global infertility market.

• Ryeqo® addresses high unmet need in endometriosis, with rapid uptake and significant patient reach.

• Menopause treatments like Lenzetto® and Vagirux® show strong growth, with Donesta® in late-stage development.

• The company is focusing on developing new molecules for endometriosis and menopause to address unmet needs.